VivoSim Labs, Inc.(VIVS)
Life Sciences Tools & Services
Preclinical & Toxicology Services
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership changeShares owned | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-11-19 | Gobel David Director | Sale | +3,266 | +16.66%22,873 | $2.24 | $7,300 | View SEC filing | |
| 2023-11-17 | Gobel David Director | Sale | -19,607 | -50.00%19,607 | $1.62 | $31,750 | View SEC filing | |
| 2021-08-19 | Cohen Douglas Jay Director | Purchase | +10,750 | +860.00%12,000 | $6.73 | $72,296 | View SEC filing | |
| 2019-08-19 | Hughes Steven George Chief Medical Officer | Sale | -22,230 | -13.83%138,484 | $0.29 | $6,431 | View SEC filing | |
| 2018-11-13 | Presnell Sharon Collins Chief Scientific Officer | Sale | -40,000 | -12.04%292,193 | $1.27 | $50,800 | View SEC filing | |
| 2017-12-04 | Murphy Keith Other | Purchase | +335,500 | +5.56%6,373,673 | $1.49 | $501,307 | View SEC filing | |
| 2017-02-10 | Murphy Keith Chairman, CEO and President | Sale | -25,000 | -0.41%6,043,915 | $3.68 | $92,035 | View SEC filing | |
| 2017-01-25 | Murphy Keith Chairman, CEO and President | Sale | -25,000 | -0.41%6,038,915 | $3.51 | $87,656 | View SEC filing | |
| 2016-12-15 | Murphy Keith Chairman, CEO and President | Sale | -50,000 | -0.82%6,063,915 | $3.72 | $185,955 | View SEC filing | |
| 2016-08-09 | David Eric CSO & EVP Pre-Clinical Dev | Sale | -20,000 | -2.75%706,306 | $4.55 | $91,000 | View SEC filing | |
| 2015-09-23 | Baltera Robert Jr. Director | Sale | -6,000 | -4.15%138,506 | $4.03 | $24,193 | View SEC filing | |
| 2015-08-13 | GLOVER JAMES T Director | Purchase | +10,000 | +100.00%10,000 | $2.80 | $28,000 | View SEC filing | |
| 2015-08-13 | Murphy Keith Chairman, CEO and President | Purchase | +20,000 | +0.34%5,944,328 | $2.56 | $51,188 | View SEC filing | |
| 2014-12-31 | MICHAELS BARRY D Chief Financial Officer | Sale | -15,000 | -4.99%285,646 | $7.50 | $112,521 | View SEC filing | |
| 2014-12-31 | David Eric Chief Strategy Officer | Sale | -20,000 | -2.87%681,306 | $7.55 | $150,997 | View SEC filing | |
| 2014-10-08 | Presnell Sharon Collins EVP, Research & Dev & CTO | Sale | -50,000 | -67.51%24,064 | $6.11 | $305,475 | View SEC filing | |
| 2014-09-16 | David Eric Chief Strategy Officer | Sale | -30,000 | -4.10%701,306 | $7.30 | $218,973 | View SEC filing | |
| 2014-02-21 | Renard Michael EVP of Commercial Operations | Sale | -10,000 | -100.00%0 | $10.65 | $106,500 | View SEC filing | |
| 2014-02-20 | Murphy Keith Chairman, CEO and President | Sale | -100,000 | -1.65%5,974,643 | $9.82 | $982,220 | View SEC filing | |
| 2014-01-29 | Renard Michael EVP of Commercial Operations | Sale | -40,000 | -100.00%0 | $9.68 | $387,199 | View SEC filing | |
| 2014-01-23 | Murphy Keith Chairman, CEO and President | Sale | -100,000 | -1.61%6,101,748 | $10.86 | $1,086,200 | View SEC filing | |
| 2013-12-18 | MICHAELS BARRY D Chief Financial Officer | Sale | -85,353 | -14.51%502,813 | $9.07 | $774,160 | View SEC filing | |
| 2013-12-12 | Murphy Keith Chairman, CEO and President | Sale | -100,000 | -1.59%6,201,748 | $10.08 | $1,007,530 | View SEC filing | |
| 2013-11-15 | Murphy Keith Chairman, CEO and President | Sale | -100,000 | -1.56%6,301,748 | $9.64 | $963,830 | View SEC filing | |
| 2013-11-15 | David Eric Chief Strategy Officer | Sale | -16,470 | -2.20%731,306 | $10.39 | $171,105 | View SEC filing |
1-25 of 32